NCT05105048View on ClinicalTrials.gov

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

August 10, 2023

Study Completion Date

August 10, 2023

Conditions

Cytomegalovirus Infection

Interventions

BIOLOGICAL

mRNA-1647

Lyophilized product that is reconstituted with saline

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (3)

91606

Velocity Clinical Research, North Hollywood

92123

California Research Foundation, San Diego

96814

East-West Medical Research Institute, Honolulu

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY

NCT05105048 - A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 | Biotech Hunter | Biotech Hunter